Xenetic Biosciences, Inc. (XBIO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.10
- As of
Kresmion compiles this page from XBIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Xenetic Biosciences, Inc. (XBIO): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-23.
See the full XBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for XBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the XBIO dossierActive signals for XBIO
- mediumEARNINGS_MISS
Q4-2024: Missed consensus by 233.3% - EPS $-0.68 vs $-0.204 estimate
- mediumEARNINGS_MISS
Q3-2024: Missed consensus by 96.1% - EPS $-0.28 vs $-0.1428 estimate
- mediumEARNINGS_MISS
Missed consensus by 233.3% - EPS $-0.68 vs $-0.204 estimate
- mediumEARNINGS_BEAT
Q1-2025: Beat consensus by 19.7% - EPS $-0.59 vs $-0.7344 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 31.1% - EPS $-0.45 vs $-0.6528 estimate
FREE, NO ACCOUNT
Every signal on XBIO, as it fires
New filings, 13F moves and cross asset signals on XBIO land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in XBIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 984015602 · 2026Q2 | $342K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, XBIO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
XBIO against its peers
XBIO's operating margin of -95.2% ranks in the 77th percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | XBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 3.0M USD | 391743 USD | 75 | 13 |
| Revenue YoY | n/a | -39.9% | n/a | 5 |
| Gross margin | n/a | 86.6% | n/a | 5 |
| Operating margin | -95.2% | -1083.7% | 77 | 10 |
| Net margin | -90.1% | -1085.3% | 77 | 10 |
| Return on equity | -36.2% | -128.5% | 97 | 16 |
| 1 year | -60.9% | -79.1% | 71 | 11 |
Peers (20): LNAI, KAPA, DRMA, SNGX, GLMD, CDIO, PULM, BGMS, LEXX, NCNA, APTOF, EMMA, PCSA, EVGN, CLGN, PMCB, AAGH, GRI, CANF, ALZN. Left out: LIMN (no annual filing), XTLB (period gap), ADXN (period gap), BVAXF (no annual filing), ENLV (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (XBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow XBIO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XBIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.